Aug 20 |
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
|
Aug 8 |
iTeos Therapeutics GAAP EPS of -$0.18
|
Aug 8 |
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
|
Aug 8 |
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
Aug 5 |
iTeos Therapeutics appoints David Feltquate as chief medical officer
|
Aug 5 |
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
|
Jul 9 |
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial
|
Jul 9 |
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
|
Jul 8 |
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
|
Jun 18 |
iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC
|